Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant DiseaseElodie Collinge, Xavier Thomas, Sandrine Loron et al.|Clinical Lymphoma Myeloma & Leukemia|2018Cited by 10
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric StudyGrégoire Le Meur, Maël Heiblig, Pierre Sujobert et al.|Transplantation and Cellular Therapy|2022Cited by 10
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDYXavier Thomas, Gilles Salles, Marica Laurino et al.|Mediterranean Journal of Hematology and Infectious Diseases|2020Cited by 5
Impact of <i>DNMT3a</i> Status on Post Induction <i>NPM1</i> MRD Predictive Value on Survival in Elderly AML Patients Treated IntensivelyMaël Heiblig, Claude Preudhomme, Hélène Labussière et al.|Blood|2020Cited by 1
Thrombocytosis drives alteration of primary hemostasis and acquired von willebrand syndrome occurrence in myeloproliferative neoplasmsGabriel Antherieu, Maël Heiblig, Hamdi Rezigue et al.|Blood|2025Cited by 1